Down syndrome (DS) is one of the most common chromosomal abnormalities affecting about 1 of every 700 fetuses. Current screening strategies have detection rates of 90鈥?5% at a 5% false positive rate. The aim of this study was to discover new biomarkers of DS in amniotic fluid by using a multiplex selected reaction monitoring assay. Nine proteins were analyzed: CEL, CPA1, MUC13, CLCA1, MUC5AC, PLUNC, and HAPLN1, and CGB as positive control and serotransferrin as negative control. One proteotypic peptide for each protein was selected, and internal heavy isotope-labeled peptide standards were spiked into the samples. Fifty-four samples from pregnant women carrying normal (
n = 37) or DS-affected (
n = 17) fetuses were analyzed. The median protein concentrations for DS and normal samples, respectively, were as follows: 20 and 49 ng/mL (
p < 0.01) for CEL; 3.7 and 14 ng/mL (
p < 0.001) for CPA1; 80 and 263 ng/mL (
p < 0.001) for MUC13; 46 and 135 ng/mL (
p < 0.001) for CLCA1; 0.65 and 0.93 渭g/mL (
p < 0.05) for MUC5AC; 61 and 73 ng/mL (
p > 0.05) for PLUNC; 144 and 86 ng/mL (
p < 0.01) for HAPLN1; 0.89 and 0.54 渭g/mL (
p = 0.05) for CGB; 91 and 87 渭g/mL (
p > 0.05) for serotransferrin. Statistically significant differences were found in six out of the seven candidate proteins analyzed, reflecting a different regulation in DS.
Keywords:
amniotic fluid; biomarker; Down鈥檚 syndrome; CEL; CLCA1; CPA1; HAPLN1; MUC13; MUC5AC